AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
10.75
+0.02 (0.19%)
Sep 5, 2025, 12:36 PM - Market open
AngioDynamics Revenue
In the fiscal year ending May 31, 2025, AngioDynamics had annual revenue of $292.50M, down -3.76%. AngioDynamics had revenue of $80.16M in the quarter ending May 31, 2025, with 12.93% growth.
Revenue (ttm)
$292.50M
Revenue Growth
-3.76%
P/S Ratio
1.50
Revenue / Employee
$433,330
Employees
675
Market Cap
436.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 292.50M | -11.42M | -3.76% |
| May 31, 2024 | 303.91M | -34.84M | -10.28% |
| May 31, 2023 | 338.75M | 22.53M | 7.13% |
| May 31, 2022 | 316.22M | 25.21M | 8.66% |
| May 31, 2021 | 291.01M | 26.85M | 10.17% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ANGO News
- 19 days ago - AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul - Seeking Alpha
- 4 weeks ago - AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 5 weeks ago - AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia - Business Wire
- 6 weeks ago - AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology - Business Wire
- 7 weeks ago - AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting - Benzinga
- 7 weeks ago - AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth - Business Wire
- 2 months ago - AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025 - Business Wire